Search

MSK researchers have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.

… Thursday, July 11, 2024 Mutations in the KRAS gene are the primary driver of  pancreatic cancer . A new class of drugs known as KRAS inhibitors is showing initial promise in clinical trials, but many tumors quickly develop resistance to the treatment. Now, researchers at Memorial Sloan Kettering Cancer

Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases.

… Wednesday, October 1, 2008 Summary Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases. Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases. In the clinic he cares for cancer patients with a wide variety

MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.

… Thursday, July 1, 2021 One of the most exciting recent developments in cancer care has been the increased use of liquid biopsies to analyze tumors. These tests, which are noninvasive and only require blood for testing, enable doctors to determine the genetic mutations driving the growth of a patient’

Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.

… Monday, July 11, 2022 Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from Memorial Sloan Kettering Cancer Center (MSK) published in JAMA Surgery .  (

To help some patients to overcome leukemia, MSK doctors are calling upon patients’ microbiomes — the vast ecosystems of microorganisms that live within us, especially the gut. These microbes appear to help some patients recover from bone marrow and stem cell transplants.

… Friday, April 1, 2022 Bridget Anderson and Charlie Gerstung at the Red Rocks Amphitheatre in Colorado. After recovering from her cord blood transplant, Bridget Anderson, shown here with now-husband Charlie Gerstung, was finally able to travel to Red Rocks in Colorado. Summary To help some patients to

Seven GSK PhD students were awarded nine competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).

… Wednesday, September 13, 2023 This past academic year, seven PhD students enrolled at  the Gerstner Sloan Kettering Graduate School of Biomedical Sciences  (GSK) were awarded nine competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science

Researchers from Memorial Sloan Kettering Cancer Center to present the latest advances in blood cancer during The American Society of Hematology 2024 annual meeting.

… Saturday, December 7, 2024 Today researchers at Memorial Sloan Kettering Cancer Center (MSK) reported  results from the first ever clinical trial to show that a high fiber plant based dietary intervention may delay progression to multiple myeloma, a type of rare, incurable blood cancer affecting the

About a third of patients with metastatic breast cancer don’t respond well to the standard anti-estrogen therapies; to find ways to better treat those patients, Memorial Sloan Kettering Cancer Center is studying three new selective estrogen receptor down-regulators (SERDs) in clinical trials.

… Thursday, June 23, 2016 While breast cancer is the most common cancer occurring in women worldwide, it is no longer considered to be a single disease. The presence or absence of an estrogen receptor, a progesterone receptor, and a protein called HER2 distinguish the subtypes of invasive breast cancer

MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.

… Tuesday, December 17, 2024 Researchers at Memorial Sloan Kettering Cancer Center (MSK) continued to make strides against cancer in 2024. Laboratory research teams across the institution worked to advance the global understanding of cancer and to develop new therapies, while also making fundamental insights

Memorial Sloan Kettering Cancer Center recently published two retrospective studies with practice-changing insights for improving the treatment and surveillance of patients with oropharyngeal cancer.

… Friday, December 19, 2025 Teams of head and neck radiation oncologists, surgical oncologists and medical oncologists at Memorial Sloan Kettering Cancer Center (MSK) recently published two retrospective studies with practice-changing insights for improving the treatment and surveillance of patients with